Expect AZ To Hike Byetta's Price Ahead Of Teva's Generic
Executive Summary
AstraZeneca PLC entered into a patent litigation settlement with Teva, giving the latter company the OK to market a generic version of Byetta (exenatide), a glucagon-like peptide-1 receptor agonist approved in the US to treat type 2 diabetes, beginning in October 2017. But before then, AstraZeneca is likely to hike Byetta's price – possible a few times.
You may also be interested in...
Express Scripts Diabetes Program Caps Drug Costs, Targets Adherence
New PBM management program aims to cut in half the projected increases in diabetes drug spending in 2017, improve patient adherence rates by 5%.
Drug Price Competition: An 'Eye-Of-The-Beholder' Debate
It was like the Pharmaceutical Research and Manufacturers of America (PhRMA) took a page straight out of the payer groups' and generic lobbyists' playbooks – declaring competition is the best way to drive down the prices of expensive medicines.
Lilly's Trulicity OK'd; can it top GLP-1 market?
Watch out Novo Nordisk, GlaxoSmithKline and AstraZeneca.